KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Gains from Sales and Divestitures (2016 - 2021)

Historic Gains from Sales and Divestitures for Abbott Laboratories (ABT) over the last 12 years, with Q4 2021 value amounting to $6.5 million.

  • Abbott Laboratories' Gains from Sales and Divestitures fell 920.62% to $6.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was $6.5 million, marking a year-over-year decrease of 920.62%. This contributed to the annual value of $6.5 million for FY2021, which is 920.62% down from last year.
  • Per Abbott Laboratories' latest filing, its Gains from Sales and Divestitures stood at $6.5 million for Q4 2021, which was down 920.62% from $7.2 million recorded in Q4 2020.
  • Over the past 5 years, Abbott Laboratories' Gains from Sales and Divestitures peaked at $7.8 million during Q4 2019, and registered a low of $6.5 million during Q4 2021.
  • In the last 5 years, Abbott Laboratories' Gains from Sales and Divestitures had a median value of $7.5 million in 2018 and averaged $7.3 million.
  • Per our database at Business Quant, Abbott Laboratories' Gains from Sales and Divestitures soared by 2929.39% in 2017 and then tumbled by 920.62% in 2021.
  • Abbott Laboratories' Gains from Sales and Divestitures (Quarter) stood at $7.6 million in 2017, then fell by 0.42% to $7.5 million in 2018, then grew by 3.03% to $7.8 million in 2019, then decreased by 7.52% to $7.2 million in 2020, then dropped by 9.21% to $6.5 million in 2021.
  • Its Gains from Sales and Divestitures stands at $6.5 million for Q4 2021, versus $7.2 million for Q4 2020 and $7.8 million for Q4 2019.